← Back to Search

Antiviral

Valganciclovir for Cytomegalovirus Retinitis

Phase 3

Waitlist Available

Research Sponsored by Hoffmann-La Roche

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Females who can have children must have a negative pregnancy test before entering the study

Patients must have active CMV retinitis that needs treatment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study whether valganciclovir is effective and safe in treating CMV retinitis in patients with AIDS who cannot take drugs by injection.

Who is the study for?

This trial is for adults over 18 with HIV and active CMV retinitis, who have had issues with injectable medications. They must not be on dialysis, involved in other drug studies, or have taken experimental drugs recently. Participants need to use birth control and cannot be pregnant or breastfeeding.Check my eligibility

What is being tested?

The study provides access to valganciclovir, an oral medication still under review, as a treatment for CMV retinitis in HIV patients. It's being tested for safety and effectiveness as an alternative to injectable treatments.See study design

What are the potential side effects?

While the specific side effects are not listed here, similar drugs can cause digestive problems, blood cell changes, potential kidney issues and may interact with other medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman who can have children and have a negative pregnancy test.

Select...

I need treatment for active CMV retinitis.

Select...

I am 18 years old or older.

Select...

I have experienced issues with receiving injections.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor

2,431 Previous Clinical Trials

1,089,568 Total Patients Enrolled

13 Trials studying Cytomegalovirus Retinitis

1,833 Patients Enrolled for Cytomegalovirus Retinitis

Media Library

Valganciclovir (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT00017784 — Phase 3

Cytomegalovirus Retinitis Research Study Groups:

Cytomegalovirus Retinitis Clinical Trial 2023: Valganciclovir Highlights & Side Effects. Trial Name: NCT00017784 — Phase 3

Valganciclovir (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00017784 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I join the ranks of this trial?

"Eligible patients for this clinical study must have a diagnosis of cytomegalovirus retinitis and be between the ages of 18 and 65. Up to 500 participants will be accepted into the trial."

Answered by AI